PMID- 38485600
OWN - NLM
STAT- Publisher
LR  - 20240314
IS  - 1532-1770 (Electronic)
IS  - 1521-6942 (Linking)
DP  - 2024 Mar 13
TI  - Dendritic cells and antigen-specific immunotherapy in autoimmune rheumatic 
      diseases.
PG  - 101940
LID - S1521-6942(24)00011-1 [pii]
LID - 10.1016/j.berh.2024.101940 [doi]
AB  - Dendritic cells (DCs) are professional antigen-presenting cells and trigger 
      downstream immune responses to antigen while integrating cellular pathogen and 
      damage-associated molecular pattern (PAMP and DAMP) or immunomodulatory signals. 
      In healthy individuals, resting and tolerogenic DCs draining skin and intestine 
      facilitate expansion of regulatory T cells (Treg) to maintain peripheral 
      antigen-specific immune tolerance. In patients with rheumatic diseases, however, 
      DCs activated by PAMPs and DAMPs expand self-reactive effector T cells, including 
      follicular helper T cells that promote the expansion of activated autoreactive B 
      cells, chronic inflammation and end-organ damage. With the development of 
      cellular and nanoparticle (NP)-based self-antigen-specific immunotherapies we 
      here consider the new opportunities and the challenges for restoring 
      immunoregulation in the treatment and prevention of autoimmune inflammatory 
      rheumatic conditions through DCs.
CI  - Copyright (c) 2024. Published by Elsevier Ltd.
FAU - Cai, Benjamin
AU  - Cai B
AD  - Frazer Institute, The University of Queensland, Brisbane, Queensland, Australia. 
      Electronic address: b.cai@uq.edu.au.
FAU - Thomas, Ranjeny
AU  - Thomas R
AD  - Frazer Institute, The University of Queensland, Brisbane, Queensland, Australia. 
      Electronic address: ranjeny.thomas@uq.edu.au.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20240313
PL  - Netherlands
TA  - Best Pract Res Clin Rheumatol
JT  - Best practice & research. Clinical rheumatology
JID - 101121149
SB  - IM
OTO - NOTNLM
OT  - Antigen-specific immunotherapy
OT  - Dendritic cells
OT  - Rheumatic diseases
OT  - Translational research
COIS- Declaration of competing interest RT reports issued patent 9,017,697 B2: 2006 
      surrounding technology for targeting DCs for antigen-specific tolerance, and 
      funding from Janssen Biotech Inc. to Uniquest resulting in development and trial 
      of DEN-181.
EDAT- 2024/03/15 00:43
MHDA- 2024/03/15 00:43
CRDT- 2024/03/14 23:00
PHST- 2024/02/27 00:00 [received]
PHST- 2024/02/29 00:00 [accepted]
PHST- 2024/03/15 00:43 [medline]
PHST- 2024/03/15 00:43 [pubmed]
PHST- 2024/03/14 23:00 [entrez]
AID - S1521-6942(24)00011-1 [pii]
AID - 10.1016/j.berh.2024.101940 [doi]
PST - aheadofprint
SO  - Best Pract Res Clin Rheumatol. 2024 Mar 13:101940. doi: 
      10.1016/j.berh.2024.101940.